Skip to main content
OpenTrials
Completed

NCT Number: NCT06897657

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

This was a retrospective non-interventional study (NIS) of adult (≥18 years) multiple sclerosis (MS) patients on ofatumumab therapy in the United Kingdom (UK) using secondary data. UK MS centers with National Health Service (NHS) databases and/or homecare and pharmacy services prescribing ofatumumab were identified and recruited for study participation using a feasibility assessment exercise. The study index identification window spanned from 26 March 2021 to 30 June 2023 (or latest data available prior to start of study data extraction). The index date was defined as the first date ofatumumab was dispensed or injected within the index identification window. From index date, patients were followed up until death, up to 13 months after index date, loss to follow-up, or end of study index identification window (whichever came first).

For patients who consented to the use of their data, participating sites transcribed protocol required patient data from existing individual patient medical records into an electronic case report form (eCRF). The end of study was defined as the date of last data query resolution (i.e., all data had been recorded in the eCRF and all data queries resolved to allow database lock to occur). This ensured that all data was available to answer the research questions in the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Sclerosis, Relapsing-Remitting Autoimmune Diseases Autoimmune Diseases of the Nervous System Behavior Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Health Behavior Immune System Diseases Medication Adherence Multiple Sclerosis Nervous System Diseases Patient Acceptance of Health Care Patient Compliance Treatment Adherence and Compliance

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Novartis

East Hanover, New Jersey, 07936, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients were included in the study if they met all of the following criteria:

  • Patient was prescribed ofatumumab within the UK approved marketing authorization
  • Patient initiated ofatumumab via participating MS clinic with or without KC PSP
  • Patients initiated ofatumumab during the index identification window
  • Authorized to collect study data:
  • Patient was alive at start of data collection and patient consented prior to start of their data collection or,
  • Patient was deceased at start of data collection and a member of the patient's direct care team had a pre-existing right to access patient medical record
  • Specifically for adherence analyses: Patients were required to have a minimum of 6 months of follow-up post index date available to make this assessment
  • Specifically for clinical effectiveness analyses: Patients were required to have a minimum of 6 months look-back pre-index date and minimum 6 months follow-up post index date available to make this assessment.

Exclusion criteria

Patients were excluded from the study if they met the following criteria:

  • Patient prescribed ofatumumab outside the approved marketing authorization (i.e., under off-label prescribing) at any point within the patients record

Treatment and study plan

Primary outcomes

  1. Medical Possession Ratio (MPR)

    Time frame: Up to 13 months

    MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period.

  2. Number of Patients by MPR Category

    Time frame: Up to 13 months

    MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:

    • High MPR: MPR = 1.0
    • Intermediate MPR: 0.8 ≤ MPR <1.0
    • Low MPR: MPR <0.8.

Secondary outcomes

  1. Number of Patients by Demographic Category

    Time frame: Baseline

    Demographic categories included:

    • Age group
    • Gender
    • Ethnicity
    • Socioeconomic status (most deprived to least deprived)
    • Decade of MS diagnosis
    • Prior disease modifying treatment (DMT) treatment status (treatment naïve or received prior DMT)

  2. Time From MS Diagnosis to Ofatumumab Initiation

    Time frame: Baseline

  3. Number of Patients by Comorbidity

    Time frame: Baseline

  4. Number of Patients who Received at Least one DMT Prior to Ofatumumab Initiation

    Time frame: Up to 13 months

  5. Number of Prior DMTs Reported

    Time frame: Up to 13 months

  6. Number of Patients by Prior DMT Category

    Time frame: Up to 13 months

    DMT categories included:

    • Type of prior DMT
    • Efficacy of DMT (moderate efficacy, more effective, high efficacy)
    • Use of injectable DMT
    • Type of injectable DMT

  7. Number of Patients by Reason for Switch from Other DMT to Ofatumumab

    Time frame: Up to 13 months

  8. Individual Annualized Relapse Rate (ARR) Before Ofatumumab Initiation

    Time frame: Up to 13 months

    Individual ARR was derived per patient as [(number of confirmed MS relapses) / (time at risk (years)].

  9. Total ARR Before Ofatumumab Initiation

    Time frame: Up to 13 months

    Total ARR was derived as [(total number of confirmed MS relapses) / (total number of person-years at risk)].

  10. Individual ARR After Ofatumumab Initiation

    Time frame: Up to 13 months

    Individual ARR was derived per patient as [(number of confirmed MS relapses) / (time at risk (years)].

  11. Total ARR After Ofatumumab Initiation

    Time frame: Up to 13 months

    Total ARR was derived as [(total number of confirmed MS relapses) / (total number of person-years at risk)].

  12. Average Expanded Disability Status Scale (EDSS) Score Before Ofatumumab Initiation

    Time frame: Up to 13 months

    The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score is determined between 0 (normal) and 10 (death due to MS).

  13. Average EDSS Score After Ofatumumab Initiation

    Time frame: Up to 13 months

    The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score is determined between 0 (normal) and 10 (death due to MS).

  14. Absolute Change in Average EDSS Score

    Time frame: Up to 26 months

    Absolute change in average EDSS score between 2 study periods was derived as: [mean EDSS score during the follow-up period] - [mean EDSS score during the pre-index period]. The index date was defined as the first date ofatumumab was dispensed or injected within the index identification window.

    The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score is determined between 0 (normal) and 10 (death due to MS).

  15. Average Number of T1 and T2 Lesions Before Ofatumumab Initiation

    Time frame: Up to 13 months

  16. Average Number of T1 and T2 Lesions After Ofatumumab Initiation

    Time frame: Up to 13 months

  17. Individual ARR After Ofatumumab Initiation by MPR Category

    Time frame: Up to 13 months

    Individual ARR was derived per patient as [(number of confirmed MS relapses) / (time at risk (years)].

    MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:

    • High MPR: MPR = 1.0
    • Intermediate MPR: 0.8 ≤ MPR <1.0
    • Low MPR: MPR <0.8.

  18. Total ARR After Ofatumumab Initiation by MPR Category

    Time frame: Up to 13 months

    Total ARR was derived as [(total number of confirmed MS relapses) / (total number of person-years at risk)].

    MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:

    • High MPR: MPR = 1.0
    • Intermediate MPR: 0.8 ≤ MPR <1.0
    • Low MPR: MPR <0.8.

  19. Average EDSS Score Before Ofatumumab Initiation by MPR Category

    Time frame: Up to 13 months

    The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score is determined between 0 (normal) and 10 (death due to MS).

    MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:

    • High MPR: MPR = 1.0
    • Intermediate MPR: 0.8 ≤ MPR <1.0
    • Low MPR: MPR <0.8.

  20. Average EDSS Score After Ofatumumab Initiation by MPR Category

    Time frame: Up to 13 months

    The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score is determined between 0 (normal) and 10 (death due to MS).

    MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:

    • High MPR: MPR = 1.0
    • Intermediate MPR: 0.8 ≤ MPR <1.0
    • Low MPR: MPR <0.8.

  21. Absolute Change in Average EDSS Score by MPR Category

    Time frame: Up to 26 months

    Absolute change in average EDSS score between 2 study periods was derived as: [mean EDSS score during the follow-up period] - [mean EDSS score during the pre-index period]. The index date was defined as the first date ofatumumab was dispensed or injected within the index identification window.

    The EDSS is a tool used to measure how much a person is affected by their MS. It consists of 8 functional systems (FS): Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the patients score was determined between 0 (normal) and 10 (death due to MS).

    MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:

    • High MPR: MPR = 1.0
    • Intermediate MPR: 0.8 ≤ MPR <1.0
    • Low MPR: MPR <0.8.

  22. Number of Patients per MPR Category by Type of KC PSP Services Received

    Time frame: Up to 13 months

    KC PSP services included face-to-face nurse visits, virtual nurse visits, and mobile text reminders.

    MPR was reported as the number of days covered by ofatumumab injections in a given time period, divided by the number of days in the time period. MPR categories:

    • High MPR: MPR = 1.0
    • Intermediate MPR: 0.8 ≤ MPR <1.0
    • Low MPR: MPR <0.8.

  23. Number of Medical Visits After Ofatumumab Initiation

    Time frame: Up to 13 months

    Medical visits included accident and emergency (A&E) visits, inpatient visits, and outpatient visits.

  24. Annualized Medical Visit Rate After Ofatumumab Initiation

    Time frame: Up to 13 months

    Annualized medical visit rate per patient was calculated as [(number of events during follow-up period) / (time at risk (years) during follow-up period)]. Rates were calculated for the following types of medical visits: A&E visits, inpatient visits, and outpatient visits.

  25. Number of MS-related Medical Visits After Ofatumumab Initiation

    Time frame: Up to 13 months

    MS-related medical visits included A&E visits, inpatient visits, and outpatient visits.

  26. Annualized MS-related Medical Visit Rate After Ofatumumab Initiation

    Time frame: Up to 13 months

    Annualized MS-related medical visit rate per patient was calculated as [(number of events during follow-up period) / (time at risk (years) during follow-up period)]. Rates were calculated for the following types of MS-related medical visits: A&E visits, inpatient visits, and outpatient visits.

  27. Number of Patients With Medically Reported Adherence (MRA) After Ofatumumab Initiation

    Time frame: Up to 13 months

    Full adherence was defined as no record of dose/s missed between ofatumumab initiation and the point at which the patient was censored. Partial adherence was defined as a record of at least one dose missed between ofatumumab initiation and the point at which the patient was censored. The date of censoring was defined as the earliest of the following:

    • End of the study follow-up (13 months)
    • Death
    • Lost to follow-up
    • End of study index identification period

  28. Number of Patients by Reason for Discontinuation of Ofatumumab

    Time frame: Up to 13 months

  29. Number of Patients who Switched From Ofatumumab to an Alternative DMT

    Time frame: Up to 13 months

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

Retrospective, Non-interventional Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Mar 27, 2025
Registry last updated
Mar 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.